Company news
Nurexone Biologic Inc news in 2022
Nurexone Biologic Inc's news releases, calls and decks from 2022, newest first.
NurExone Issues Annual Shareholder Letter
December 15, 2022
NurExone Announces Completion of Securites for Debt Settlement
December 7, 2022
Update: NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
December 1, 2022
NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
November 30, 2022
NurExone Announces Securities for Debt Settlement
November 24, 2022
NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 24, 2022
NurExone Announces Completion of Securities for Debt Settlements
November 8, 2022
NurExone Announces Plan to Submit Pre-Investigational New Drug Meeting Request to U.S. Food and Drug Administration
November 2, 2022
NurExone Announces Productivity and Quality Pilot Results of Patent-Pending Process for 3D Scaled Up Exosome Production
October 26, 2022
NurExone Biologic to Participate in 2022 Bio-Europe Conference
October 20, 2022
UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven Technology
October 12, 2022
NurExone Signs Letter of Intent with Nanometrix For its Exosome and Cargo Molecular Profiling AI-Driven Technology
October 12, 2022
NurExone Announces Scientific Survey Results of Proprietary Exosome-based Technology
October 4, 2022
NurExone Announces Additional Securities for Debt Settlement
October 3, 2022
NurExone Announces Letter of Intent for International Strategic Collaboration with denovoMATRIX Towards Large-Scale Exosome Production
September 7, 2022
NurExone Announces Securities Issuing at Premium over Current Share Price to Settle EnerSpar's Debts Prior to RTO Transaction
September 1, 2022
NurExone Reports Second Quarter 2022 Financial Results and Provides Business Update
August 25, 2022
James Richardson, the Former CEO of EnerSpar, Updates Shareholders After the Completion of RTO with NurExone Biologic
August 9, 2022
NurExone Announces Sponsorship and Participation in Gordon Research's 2022 Extracellular Vesicles Conference in Maine, U.S.
July 25, 2022
NurExone Exosomes to Be Used in Cutting Edge Molecular Research at Hebrew University's Burstyn-Cohen Lab
July 19, 2022
NurExone Provides Corporate Update
July 13, 2022
NurExone to Collaborate with Polyrizon for Intranasal Administration of Cutting-Edge Exosome-Therapy
July 11, 2022
NurExone to Host Investor Webinar on Thursday, July 14, 2022
July 7, 2022
NurExone Biologic Inc. Retains Services of Thesis Capital Inc
July 6, 2022
NurExone Biologic Inc. Opens the Market
July 5, 2022
NurExone Biologic Inc. to Begin Trading on TSX Venture Exchange and Retains Market Maker
June 22, 2022
Decks in 2022
- Investor Presentation (September 2022)
Investor deck · 21 slides · September 2022